JP4963607B2 - 神経再生及び機能回復のためのシグマリガンド - Google Patents

神経再生及び機能回復のためのシグマリガンド Download PDF

Info

Publication number
JP4963607B2
JP4963607B2 JP2006533806A JP2006533806A JP4963607B2 JP 4963607 B2 JP4963607 B2 JP 4963607B2 JP 2006533806 A JP2006533806 A JP 2006533806A JP 2006533806 A JP2006533806 A JP 2006533806A JP 4963607 B2 JP4963607 B2 JP 4963607B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
sigma
administration
functional recovery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006533806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500757A (ja
JP2007500757A5 (enExample
Inventor
オクセンバーグ，ドナ
アーファー，ローマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MS Science Corp
Original Assignee
MS Science Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MS Science Corp filed Critical MS Science Corp
Publication of JP2007500757A publication Critical patent/JP2007500757A/ja
Publication of JP2007500757A5 publication Critical patent/JP2007500757A5/ja
Application granted granted Critical
Publication of JP4963607B2 publication Critical patent/JP4963607B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006533806A 2003-06-12 2004-06-14 神経再生及び機能回復のためのシグマリガンド Expired - Fee Related JP4963607B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47832903P 2003-06-12 2003-06-12
US47873503P 2003-06-12 2003-06-12
US60/478,735 2003-06-12
US60/478,329 2003-06-12
US49813203P 2003-08-26 2003-08-26
US60/498,132 2003-08-26
US55261304P 2004-03-12 2004-03-12
US60/552,613 2004-03-12
PCT/US2004/019139 WO2004110387A2 (en) 2003-06-12 2004-06-14 Sigma ligands for neuronal regeneration and functional recovery

Publications (3)

Publication Number Publication Date
JP2007500757A JP2007500757A (ja) 2007-01-18
JP2007500757A5 JP2007500757A5 (enExample) 2007-07-26
JP4963607B2 true JP4963607B2 (ja) 2012-06-27

Family

ID=33556648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533806A Expired - Fee Related JP4963607B2 (ja) 2003-06-12 2004-06-14 神経再生及び機能回復のためのシグマリガンド

Country Status (5)

Country Link
US (4) US7863272B2 (enExample)
EP (2) EP1635805A4 (enExample)
JP (1) JP4963607B2 (enExample)
CA (1) CA2528160C (enExample)
WO (3) WO2004110388A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003061658A1 (ja) * 2002-01-22 2005-05-19 エーザイ株式会社 インダノン誘導体を含有するシグマ受容体結合剤
US7863272B2 (en) * 2003-06-12 2011-01-04 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) * 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US20060106064A1 (en) * 2004-11-03 2006-05-18 University Of North Texas Health Science Center At Fort Worth Butyrophenones and sigma-1 receptor antagonists protect against oxidative-stress
WO2006133199A2 (en) * 2005-06-06 2006-12-14 University Of South Florida Treatment with sigma receptor agonists post-stroke
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7985751B2 (en) 2005-08-09 2011-07-26 M's Science Corporation Piperazine derivatives
US7758954B2 (en) * 2005-08-18 2010-07-20 James Hardie Technology Limited Coated substrate having one or more cross-linked interfacial zones
US20070142396A1 (en) * 2005-12-16 2007-06-21 Vela Pharmaceuticals, Inc. Treatment of pain with 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2(1H)-quinolone or salt thereof
WO2007081946A2 (en) * 2006-01-09 2007-07-19 University Of South Florida Method for the identification of drugs to treat stroke at delayed timepoints
CA2633568A1 (en) 2006-01-27 2007-08-09 M's Science Corporation Piperidine and piperazine derivatives
BRPI0908217A2 (pt) * 2008-02-18 2015-08-25 Esteve Labor Dr Uso de compostos de ligação aos ligantes do receptor sigma para o tratamento de dor neuropática desenvolvida como uma consequência de quimioterapia
DK3106166T3 (da) 2008-02-29 2021-01-11 Vm Therapeutics Llc Forbindelser til behandling af smertesyndrom og andre lidelser
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
WO2010048164A2 (en) * 2008-10-20 2010-04-29 University Of South Florida N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints
CN102197017A (zh) * 2008-10-27 2011-09-21 株式会社爱慕知科学 含苯基的环己胺衍生物和伴随中枢神经障碍的疾病的治疗药
ES2545795T3 (es) 2009-04-09 2015-09-15 Cognition Therapeutics, Inc. Inhibidores del deterioro cognitivo
EP2458983B1 (en) 2009-07-31 2015-07-08 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US20130108645A1 (en) * 2010-04-13 2013-05-02 The Johns Hopkins University Methods for enhancing axonal regeneration
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
HK1202246A1 (en) * 2011-08-25 2015-09-25 考格尼申治疗股份有限公司 Compositions and methods for treating neurodegenerative disease
KR101129303B1 (ko) * 2011-10-19 2012-03-26 경희대학교 산학협력단 플루옥세틴을 유효성분으로 함유하는 중추신경계 질환의 예방 및 치료용 약학적 조성물
WO2013166307A2 (en) * 2012-05-02 2013-11-07 University Of South Florida N,n'-di-1 naphthylguanidine hcl (nagh) and n,n'-di-p-nitrophenylguanidine hcl (nad) treatment for stroke at delayed timepoints
CA2872188C (en) 2012-05-16 2018-08-14 Sanbio, Inc. Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
DK3099296T3 (en) 2014-01-31 2019-04-15 Cognition Therapeutics Inc ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE
EP3364976A4 (en) * 2015-10-19 2019-06-05 Board of Regents, The University of Texas System PIPERAZINYL-NORBENZOMORPHAN COMPOUNDS AND METHOD FOR USE THEREOF
JP7059192B2 (ja) * 2016-02-11 2022-04-25 シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ 神経変性疾患の治療に使用するためのイグメシン
CA3022512A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
AU2018269964B2 (en) 2017-05-15 2022-07-07 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
WO2019133997A1 (en) 2017-12-31 2019-07-04 Neuroenhancement Lab, LLC System and method for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
EP3844171A4 (en) * 2018-08-31 2022-08-10 Texas Tech University System ENHANCER OF NEUROLYSIN ACTIVITY
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
CN111848549B (zh) * 2019-04-29 2022-04-22 苏州大学 芳基肟类化合物及其制备和应用
CN116867488A (zh) * 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性（amd）的组合物
JP2024531809A (ja) * 2021-09-20 2024-08-29 エステベ ファーマシューティカルズ，ソシエダッド アノニマ 運動ニューロン変性の処置又は神経保護において使用するためのオキサジアザスピロ化合物
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055470A (en) * 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
US5005470A (en) * 1989-11-09 1991-04-09 Denker James G Portable work station
US5229394A (en) * 1990-07-30 1993-07-20 Arch Development Corporation Method for treatment of amyotrophic lateral sclerosis comprising administration of dmp
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
WO1993009094A1 (en) 1991-10-30 1993-05-13 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
US5428037A (en) 1993-04-09 1995-06-27 Syntex Pharmaceuticals, Ltd. Heterocyclic derivatives in the treatment of Ischaemia and related diseases
US6087346A (en) * 1993-06-23 2000-07-11 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
KR100299734B1 (ko) * 1993-07-28 2002-01-09 모리타 다카카즈 1,4-(디페닐알킬)피페라진유도체
GB9416571D0 (en) * 1994-08-16 1994-10-12 Battelle Memorial Institute Novel alkylamino derivatives as sigma 2 selective ligands
UA64769C2 (uk) * 1997-11-07 2004-03-15 Х. Луннбек А/С Гідрогалогеніди 1'-[4-[1-(4-фторофеніл)-1н-індол-3-іл]-1-бутил]-спіро[ізобензофуран-1(3н),4'-піперидину], фармацевтична композиція та спосіб лікування
JP2002510626A (ja) * 1998-04-07 2002-04-09 ハー・ルンドベック・アクチエゼルスカベット パニック発作の治療法
US20030087840A1 (en) 1998-05-19 2003-05-08 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor
GB0007842D0 (en) * 2000-03-31 2000-05-17 Spruce Barbara Sigma receptor ligands and their medical uses
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US7863272B2 (en) * 2003-06-12 2011-01-04 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery

Also Published As

Publication number Publication date
US20050020483A1 (en) 2005-01-27
US7863272B2 (en) 2011-01-04
US20050059689A1 (en) 2005-03-17
JP2007500757A (ja) 2007-01-18
EP1644026A2 (en) 2006-04-12
WO2004110387A2 (en) 2004-12-23
WO2004110387A3 (en) 2005-08-18
EP1644026A4 (en) 2007-10-24
CA2528160C (en) 2012-01-03
EP1635805A4 (en) 2007-08-08
WO2004110389A2 (en) 2004-12-23
CA2528160A1 (en) 2004-12-23
WO2004110388A3 (en) 2005-07-28
US20050032827A1 (en) 2005-02-10
WO2004110389A3 (en) 2005-12-22
EP1635805A2 (en) 2006-03-22
WO2004110388A2 (en) 2004-12-23
US20110082154A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
JP4963607B2 (ja) 神経再生及び機能回復のためのシグマリガンド
US20110015209A1 (en) Sigma ligands for neuronal regeneration and functional recovery
US20110152284A1 (en) Sigma ligands for neuronal regeneration and functional recovery
KR101783632B1 (ko) 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
JP2020530847A (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
EA013084B1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
WO2011107583A1 (en) Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
US20200297696A1 (en) P38 inhibitors for the treatment of fshd
US20220008414A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
US11583543B2 (en) Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
JP5301474B2 (ja) ４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン塩の液体製剤
WO2023170550A1 (en) Polymorph forms of aticaprant for use in treating major depressive disorder
CN106243096B (zh) 三环类药物的新用途
CN100420483C (zh) 用于神经元再生和功能恢复的σ配体
WO2008060271A1 (en) Sigma ligands for neuronal regeneration and functional recovery
HK1131862A (en) Sigma ligands for neuronal regeneration and functional recovery
WO2007002885A2 (en) Compositions and methods for use of a sodium channel blocker
WO2011000562A1 (en) Eltoprazine for the treatment of certain movement disorders
JP2007533699A (ja) 医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070528

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120326

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150406

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees